Articles related to LEUKEMIA

Explore the latest findings on vibecotamab’s potential in R/R AML treatment, revealing promising results with an optimized dosing regimen that mitigates cytokine response syndrome while improving patient outcomes.

In light of recent findings, CD24Fc emerges as a potential game-changer in preventing acute GVHD in HSCT patients, with a notable survival rate improvement to 96.2% for severe cases.

In a recent phase 3 trial, a low-dose chemotherapy regimen demonstrated noninferior efficacy to standard-dose regimens in pediatric AML patients, while significantly reducing non-hematologic toxicities, an important consideration in pediatric oncology.

Dr. Zackon’s study reveals a stark 18% difference in mortality rates between Black and White CLL patients, underscoring the profound impact of socioeconomic factors on patient outcomes.

The study’s findings suggest that ibrutinib–venetoclax therapy could potentially revolutionize the treatment of CLL. With a significant reduction in disease progression or death at a median of 43.7 months, this therapy could offer a promising alternative to the standard FCR regimen.

The recent study on FLT3 inhibitor monotherapy brings hope to the field of oncology, particularly for patients with high-risk FLT3-mutated AML. Administered at the stage of molecular failure, the therapy has shown encouraging survival rates.